Katrina Ray

1 month ago | nature.com | Katrina Ray

A new trial, published in The Lancet, has shown that adding a single sentence with a suggested deadline for return of a faecal immunochemical test (FIT) in the invitation letter reduced the need to issue reminder letters and led to a more timely FIT return as part of a national colorectal cancer (CRC) screening programme.

2 months ago | nature.com | Katrina Ray

Vaccines to treat cancer are currently in development, with the potential for personalized treatments targeting specific mutations in various cancer types. A previous phase I trial reported that a personalized RNA neoantigen vaccine was safe and stimulated anti-tumour CD8+ T cells in patients with pancreatic cancer that correlated with delayed recurrence of pancreatic adenocarcinoma (8 of 16, at 1.5-year follow-up).

2 months ago | nature.com | Katrina Ray

Accurately determining dietary and nutrient intake in nutrition research is challenging, and usually reliant on self-reported methods such as dietary questionnaires that can introduce bias. A new study published in Nature Metabolism reports a method for quantifying food-derived DNA in human stool — Metagenomic Estimation of Dietary Intake (MEDI) — by examining faecal metagenomes. This new, semi-quantitative method could be an alternative approach for approximating dietary intake. Diener et al.

Jan 28, 2025 | nature.com | Katrina Ray

Metabolic dysfunction-associated steatohepatitis (MASH) is known to increase the risk of hepatocellular carcinoma (HCC), yet also triggers hepatocyte senescence (a tumour-suppressive cell state). New research shows that the gluconeogenic enzyme fructose-1,6-bisphophatase (FBP1) serves as a key control point in the switch from MASH to HCC.

Feb 15, 2024 | nature.com | Katrina Ray

Positive phase III results have been reported for resmetirom (a thyroid hormone receptor β-selective agonist) for the treatment of nonalcoholic steatohepatitis (NASH; also known as metabolic dysfunction-associated steatohepatitis (MASH)) with liver fibrosis. In a phase III, randomized controlled trial, 966 patients with biopsy-confirmed NASH and liver fibrosis (stage F1B, F2 or F3) were randomly assigned to receive a once-daily dose of 80 mg resmetirom, 100 mg resmetirom or placebo for 52 weeks.